Answers are grounded in this paper and cite their sources.
Aprepitant (EMEND) is the first commercially available drug from a new class o agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for preven tion of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated wit highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P ha lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of ac tivity against a wide variety of central and peripheral emetogenic stimuli make it potentially usefu in non-chemotherapy related nausea and vomiting.
No takes yet. Share an insight, caveat, or question.
Eric Prommer (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: